Revolution Medicines Q3 2026 Results: Net Loss of $407M, Loss Widens
Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.
- Key figure
- Net loss $407M